Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 7, 2023
04 January 2023 - 11:30PM
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical
company, today announced that Dr. Stephen A. Harrison, Chairman and
Co-Founder, Pinnacle Clinical Research and Summit Clinical
Research, will deliver an oral presentation of the results of
Altimmune’s recently completed 12-week Phase 1b and 12-week
extension trials of pemvidutide in subjects with non-alcoholic
fatty liver disease (NAFLD) at the NASH-TAG Conference, which will
be held in Park City, UT on January 6-7, 2023. Pemvidutide is a
novel, investigational, peptide-based GLP-1/glucagon dual receptor
agonist in development for the treatment of obesity and NASH.
Details for the oral presentation are as follows:
Title: |
Pemvidutide, a Balanced GLP-1/Glucagon Dual Receptor Agonist,
Significantly Reduces Liver Fat, Non-invasive Markers of
Fibroinflammation, and Body Weight in Patients with Non-alcoholic
Fatty Liver Disease: Results of a Multicenter, Randomized,
Double-blind, Placebo-controlled Trial |
Presenter: |
Stephen Harrison, M.D., Chairman and Co-Founder of Pinnacle
Clinical Research and Summit Clinical Research in San Antonio,
TX |
Date/Time: |
Saturday, January 7, 2023, at 10:30 am Mountain Standard Time |
A copy of the presentation will be accessible on
the Events section of the Altimmune website.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical
company focused on the development of novel peptide-based
therapeutics for the treatment of obesity and liver diseases. The
company’s lead product candidate, pemvidutide (ALT-801), is a
GLP-1/glucagon dual receptor agonist that is being developed for
the treatment of obesity and NASH. In addition, Altimmune is
developing HepTcell™, an immunotherapeutic designed to achieve a
functional cure for chronic hepatitis B. For more information,
please visit www.altimmune.com.
Follow @Altimmune, Inc. on
LinkedInFollow @AltimmuneInc on
Twitter
Investor & Media Contacts:
Richard EisenstadtChief Financial OfficerPhone:
240-654-1450reisenstadt@altimmune.com
Altimmune (NASDAQ:ALT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Altimmune (NASDAQ:ALT)
Historical Stock Chart
From Apr 2023 to Apr 2024